Am. J. Respir. Cell Mol. Biol., Volume 20, Number 4, April, 1999 543-549

Raf-1 Causes Growth Suppression and Alteration of Neuroendocrine Markers in DMS53 Human Small-Cell Lung Cancer Cells

Rajani K. Ravi, Arunthathi Thiagalingam, Erich Weber, Martin McMahon, Barry D. Nelkin, and Mack Mabry

Oncology Center, Johns Hopkins University Medical Institutions, Baltimore, Maryland; and DNAX Research Institute of Molecular and Cellular Biology, Palo Alto, California

Ras mutations are common in lung adenocarcinomas and squamous-cell cancers, which are non-small-cell lung cancers (NSCLCs). However, small-cell lung cancers (SCLCs) rarely have ras mutations, suggesting that ras activation may not confer a growth advantage in these cells. In one SCLC cell line DMS53, activated ras expression induced increased neuroendocrine differentiation and decreased cell proliferation. We show here that DMS53 cells undergo differentiation and G₁-specific growth arrest in response to ras/raf/ mitogen-activated protein kinase kinase (MEK)/mitogen-activated protein kinase (MAPK) pathway activation. To assess the consequences of activating the raf/MEK/MAPK pathway downstream of ras, we transfected a DMS53 cell line with Raf-1:ER, an activatable form of c-raf-1. Raf-1:ER activation suppressed cell proliferation and cloning on soft agar by 90% without evidence of apoptosis. Cell cycle analysis showed a reduced proportion of cells in S phase, and was associated with induction of the cyclin-dependent kinase (cdk) inhibitor p16^INK4. Expression of the cell cycle-specific proteins pRb, Rb2/p130, p107, cyclin A, cdc-2, and E2F-1 was decreased after Raf-1:ER activation in DMS53 cells. The activity cdk4 and cdk2 was also reduced, as consistent with cell cycle arrest in cells with activated Raf-1:ER cells. In addition, Raf-1:ER reduced the expression of neuroendocrine markers, gastrin releasing peptide, and ret gene in DMS53:Raf-1:ER cells. These results provide further evidence that activation of the raf/MEK/ MAPK signaling pathway, which is associated with transformation in many circumstances, can reduce the growth of SCLC cells, and suggest that activation of this pathway might be clinically efficacious in some settings.

This article has been cited by other articles:

				M. Kunnimalaiyaan and H. Chen Tumor Suppressor Role of Notch-1 Signaling in Neuroendocrine Tumors Oncologist, May 1, 2007; 12(5): 535 - 542. [Abstract] [Full Text] [PDF]

				M. Kunnimalaiyaan, A. M. Vaccaro, M. A. Ndiaye, and H. Chen Inactivation of glycogen synthase kinase-3{beta}, a downstream target of the raf-1 pathway, is associated with growth suppression in medullary thyroid cancer cells Mol. Cancer Ther., March 1, 2007; 6(3): 1151 - 1158. [Abstract] [Full Text] [PDF]

				J. J. Van Gompel, M. Kunnimalaiyaan, K. Holen, and H. Chen ZM336372, a Raf-1 activator, suppresses growth and neuroendocrine hormone levels in carcinoid tumor cells Mol. Cancer Ther., June 1, 2005; 4(6): 910 - 917. [Abstract] [Full Text] [PDF]

				E.-J. Kim, J.-I. Park, and B. D. Nelkin IFI16 Is an Essential Mediator of Growth Inhibition, but Not Differentiation, Induced by the Leukemia Inhibitory Factor/JAK/STAT Pathway in Medullary Thyroid Carcinoma Cells J. Biol. Chem., February 11, 2005; 280(6): 4913 - 4920. [Abstract] [Full Text] [PDF]

				S. Vicent, M. Garayoa, J. M. Lopez-Picazo, M. D. Lozano, G. Toledo, F. B. J. M. Thunnissen, R. G. Manzano, and L. M. Montuenga Mitogen-Activated Protein Kinase Phosphatase-1 Is Overexpressed in Non-Small Cell Lung Cancer and Is an Independent Predictor of Outcome in Patients Clin. Cancer Res., June 1, 2004; 10(11): 3639 - 3649. [Abstract] [Full Text] [PDF]

				R. S. Sippel, J. E. Carpenter, M. Kunnimalaiyaan, S. Lagerholm, and H. Chen Raf-1 activation suppresses neuroendocrine marker and hormone levels in human gastrointestinal carcinoid cells Am J Physiol Gastrointest Liver Physiol, July 7, 2003; 285(2): G245 - G254. [Abstract] [Full Text] [PDF]

				F. H. Blackhall, M. Pintilie, M. Michael, N. Leighl, R. Feld, M.-S. Tsao, and F. A. Shepherd Expression and Prognostic Significance of Kit, Protein Kinase B, and Mitogen-activated Protein Kinase in Patients with Small Cell Lung Cancer Clin. Cancer Res., June 1, 2003; 9(6): 2241 - 2247. [Abstract] [Full Text] [PDF]

				J.-I. Park, C. J. Strock, D. W. Ball, and B. D. Nelkin The Ras/Raf/MEK/Extracellular Signal-Regulated Kinase Pathway Induces Autocrine-Paracrine Growth Inhibition via the Leukemia Inhibitory Factor/JAK/STAT Pathway Mol. Cell. Biol., January 15, 2003; 23(2): 543 - 554. [Abstract] [Full Text] [PDF]

				V. Sriuranpong, M. W. Borges, R. K. Ravi, D. R. Arnold, B. D. Nelkin, S. B. Baylin, and D. W. Ball Notch Signaling Induces Cell Cycle Arrest in Small Cell Lung Cancer Cells Cancer Res., April 1, 2001; 61(7): 3200 - 3205. [Abstract] [Full Text]

				C. F. Yu, M. A. Sanders, and M. D. Basson Human Caco-2 motility redistributes FAK and paxillin and activates p38 MAPK in a matrix-dependent manner Am J Physiol Gastrointest Liver Physiol, June 1, 2000; 278(6): G952 - G966. [Abstract] [Full Text] [PDF]

				S. J. Weintraub Dormant Tumor-Suppressor Pathways in Tumors Am. J. Respir. Cell Mol. Biol., April 1, 1999; 20(4): 541 - 542. [Full Text]

				C. P. Fanton, M. McMahon, and R. O. Pieper Dual Growth Arrest Pathways in Astrocytes and Astrocytic Tumors in Response to Raf-1 Activation J. Biol. Chem., May 25, 2001; 276(22): 18871 - 18877. [Abstract] [Full Text] [PDF]